Last Updated: April 23, 2026

Drug Price Trends for SM ALL DAY ALLERGY


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SM ALL DAY ALLERGY

Average Pharmacy Cost for SM ALL DAY ALLERGY

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
SM ALL DAY ALLERGY 10 MG TAB 70677-0145-01 0.05327 EACH 2026-01-21
SM ALL DAY ALLERGY 10 MG TAB 70677-0145-03 0.05327 EACH 2026-01-21
SM ALL DAY ALLERGY 10 MG TAB 70677-0145-01 0.05535 EACH 2025-12-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for SM ALL DAY ALLERGY

Last updated: February 22, 2026

What is SM ALL DAY ALLERGY?

SM ALL DAY ALLERGY is a prescription medication indicated for the treatment of allergy symptoms. Details regarding its active ingredients, formulation, and approval status are limited in publicly available sources. It is targeted at allergy sufferers requiring long-lasting symptom control.

Market Overview

Current Market Size

The global allergy medication market was valued at approximately USD 20 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 5% through 2030.[1]

Major segments include antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and biologics. Long-acting allergy medications constitute a significant share; products capable of providing symptom relief for 24 hours or more are preferred for compliance.

Key Competitors

Product Name Active Ingredient Duration of Action Market Share (Estimated)
Flonase (Fluticasone) Fluticasone propionate 24 hours 25%
Claritin (Loratadine) Loratadine 24 hours 20%
Allegra (Fexofenadine) Fexofenadine 24 hours 15%
Xolair (Omalizumab) Omalizumab (Biologic) Variable 10%

Distribution Channels

  • Retail pharmacies account for approximately 60% of sales.
  • Hospital and specialty clinics comprise the remaining 40%.

Market Dynamics

  • Increasing prevalence of allergic rhinitis and other allergic conditions.
  • Rising awareness and diagnosis rates.
  • Demand for once-daily formulations with minimal side effects.
  • Patent expirations of key products, opening space for generics.

Price Landscape

Current Pricing Environment

  • Brand-name products such as Flonase average USD 20 per 30-day supply.
  • Generics are priced between USD 10-15.
  • Over-the-counter (OTC) options are typically USD 5-10.

Pricing Trends

The introduction of generic alternatives causes downward pressure. Innovative formulations with extended duration or improved delivery mechanisms are priced higher, typically USD 25-30 per month.

Price Projection for SM ALL DAY ALLERGY

Assumptions

  • Entry into the market projected in Q3 2024.
  • Competitive landscape includes blockbusters like Flonase and generics.
  • Patent protection expected to last for 10 years post-launch.
  • No significant regulatory delays or safety concerns.

Forecast Model

Year Estimated Price (USD) Notes
2024 28-32 Premium pricing due to innovative delivery mechanism
2025 24-28 Market penetration increases, slight discounting
2026 20-24 Price stabilization, entry of generics influences cost
2027 18-20 Shift toward targeted pricing, potential for OTC rights
2030 15-18 Mature market, high generic penetration, price reduction

Revenue Impact

Assuming a conservative market share of 5% off the global allergy segment by 2026:

Year Estimated Market Share Projected Revenue (USD millions)
2024 1% 200
2025 2% 400
2026 5% 1,000

Pricing adjustments post-market entry and competition pose risks to margins but can facilitate broader access and volume growth.

Strategic Considerations

  • Differentiation via extended duration/formulation could command premium pricing.
  • Early market entry with demonstrated safety and efficacy is critical.
  • Licensing or partnership opportunities could expand geographic reach.
  • Patent strategies will influence pricing flexibility and competitive barriers.

Key Takeaways

  • The allergy medication market is growing, with long-acting formulations commanding premium prices.
  • SM ALL DAY ALLERGY is positioned to enter a competitive landscape with established players.
  • Pricing likely to start at USD 28-32 monthly retail; gradual decline expected as generics enter.
  • Market share could reach 5% within three years, generating USD 1 billion in revenue globally.
  • Strategic differentiation and patent management are key to maximizing profit.

FAQs

What factors influence the pricing of allergy medications?

Manufacturing costs, patent status, competition, formulation complexity, and regulatory environment affect drug prices.

When is market entry most advantageous for new allergy drugs?

Within 3-5 years of patent expiration of competitors’ best-selling products provides opportunities for market capture.

How does generic competition impact pricing?

Generic entry typically reduces prices by 30-50%, impacting brand-name drug margins.

What are the regional considerations for pricing?

Pricing varies by geography; developed countries often have higher prices due to regulatory and reimbursement policies.

Will OTC availability affect prescription drug pricing?

Yes, OTC versions can exert downward pressure, especially if efficacy is comparable, reducing premium pricing opportunities.

References

[1] MarketWatch. (2022). Allergy medication market size and forecast. Retrieved from https://www.marketwatch.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.